exhibit 10. 7 dated 29th november 2017 ( 1 ) anthony nolan - and - ( 2 ) inmune bio international ltd material transfer and licence agreement this material transfer agreement together with its schedules, the " agreement " is made on 29 november 2017, the " effective date ", between ( 1 ) anthony nolan, a company incorporated in england under the companies acts with registered number # # # - # # # - # # # # and charity number 803716, and having its registered office at the royal free hospital, pond street, hampstead, london nw3 1qg england ( " an " ) ; and ( 2 ) inmune bio international ltd, a company incorporated in england under the companies acts with registered number 10105962 and having its registered office at kerman & co llp ( attn. : simon w. holden ), 200 strand, london, wc2r 1dj, england, ( " imb " ), ( 1 ) anthony nolan, a company incorporated in england under the companies acts with registered number # # # - # # # - # # # # and charity number 803716, and having its registered office at the royal free hospital, pond street, hampstead, london nw3 1qg england ( " an " ) ; and ( 2 ) inmune bio international ltd, a company incorporated in england under the companies acts with registered number 10105962 and having its registered office at kerman & co llp ( attn. : simon w. holden ), 200 strand, london, wc2r 1dj, england, ( " imb " ), together the " parties " and each a " party ". whereas : a an and the royal free hampstead nhs trust ( " rfh " ) entered into a third party service level agreement on 23 september 2016 for the procurement of msc derived from umbilical cord blood or placenta to be used for research purposes by rfh and specifically, a researcher, professor mark w lowdell ( the " rfh agreement " ). b imb was established and co - founded in april 2016 by professor mark lowdell, dr raymond joseph tesi and mr david moss. imb wishes to obtain the materials for their use in the field. c the parties have agreed that the materials are only for use in humans or for human application if approved by the relevant regulatory body and wish to enter into this agreement to govern their relationship in this